- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Corcept Therapeutics Incorporated (CORT)
Corcept Therapeutics Incorporated stock price live, this page displays NASDAQ CORT stock exchange data. View the CORT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Corcept Therapeutics Incorporated real time stock price chart below.
What Is the Corcept Therapeutics Incorporated Stock Price Today?
The Corcept Therapeutics Incorporated stock price today is 39.76.
What Is the Stock Symbol for Corcept Therapeutics Incorporated?
The stock symbol for Corcept Therapeutics Incorporated is "CORT."
What Stock Exchange Does Corcept Therapeutics Incorporated Trade On?
Corcept Therapeutics Incorporated is listed and trades on the NASDAQ stock exchange.
Is Corcept Therapeutics Incorporated a Good Stock to Buy?
Determining whether Corcept Therapeutics Incorporated—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CORT quote. (ISIN: US2183521028)
What Is the Corcept Therapeutics Incorporated Stock Price Today?
The Corcept Therapeutics Incorporated stock price today is 39.76.
What Is the Stock Symbol for Corcept Therapeutics Incorporated?
The stock symbol for Corcept Therapeutics Incorporated is "CORT."
What Stock Exchange Does Corcept Therapeutics Incorporated Trade On?
Corcept Therapeutics Incorporated is listed and trades on the NASDAQ stock exchange.
Is Corcept Therapeutics Incorporated a Good Stock to Buy?
Determining whether Corcept Therapeutics Incorporated—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CORT quote. (ISIN: US2183521028)
Currency in USD
39.76
-0.95(-2.32%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
39.71
41.36
52 wk Range
32.99
117.33
Earnings results expected in 14 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
39.7141.36
52 wk Range
32.99117.33
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CORT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
94.20
Upside
+136.92%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Corcept Therapeutics Incorporated Company Profile
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Corcept Therapeutics Incorporated Earnings Call Summary for Q3/2025
- Corcept Therapeutics reported Q3 2025 EPS of $0.16 (23.08% above forecast), while revenue missed at $207.6 million (5% below expectations), causing shares to fall 4.14% after hours
- Revenue increased 13.8% YoY to $207.6 million, but net income declined to $19.7 million from $47.2 million YoY, with cash and investments standing at $524 million
- The company maintained its 2025 revenue guidance of $800-$850 million despite the revenue miss, focusing on expansion in hypercortisolism and oncology markets
- CEO Joe Belanoff expressed confidence in meeting FDA deadlines for relacorilant approvals in both hypercortisolism and ovarian cancer, critical for future growth
- Key challenges include revenue underperformance, potential FDA approval delays, increased SG&A expenses, and market competition in the hypercortisolism space
Last Updated: 2025-11-04, 06:10 p/m
Read Full TranscriptCompare CORT to Peers and Sector
Metrics to compare | CORT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCORTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 40.4x | 17.5x | −0.6x | |
PEG Ratio | −1.32 | −0.82 | 0.00 | |
Price/Book | 6.7x | 1.9x | 2.6x | |
Price / LTM Sales | 5.7x | 2.3x | 3.3x | |
Upside (Analyst Target) | 148.3% | 8.2% | 45.0% | |
Fair Value Upside | Unlock | 16.3% | 6.5% | Unlock |
Analyst Ratings
4 Buy
1 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 94.20
(+136.92% Upside)
Earnings
Latest Release
Nov 04, 2025
EPS / Forecast
0.16 / 0.13
Revenue / Forecast
207.60M / 218.53M
People Also Watch
FAQ
What Is the Corcept (CORT) Stock Price Today?
The Corcept stock price today is 39.76
What Stock Exchange Does Corcept Trade On?
Corcept is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Corcept?
The stock symbol for Corcept is "CORT."
What Is the Corcept Market Cap?
As of today, Corcept market cap is 4.20B.
What Is Corcept's Earnings Per Share (TTM)?
The Corcept EPS (TTM) is 0.87.
When Is the Next Corcept Earnings Date?
Corcept will release its next earnings report on Feb 18, 2026.
From a Technical Analysis Perspective, Is CORT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Corcept Stock Split?
Corcept has split 0 times.
How Many Employees Does Corcept Have?
Corcept has 500 employees.
What is the current trading status of Corcept (CORT)?
As of Feb 04, 2026, Corcept (CORT) is trading at a price of 39.76, with a previous close of 40.70. The stock has fluctuated within a day range of 39.71 to 41.36, while its 52-week range spans from 32.99 to 117.33.
What Is Corcept (CORT) Price Target According to Analysts?
The average 12-month price target for Corcept is USD94.20, with a high estimate of USD121 and a low estimate of USD50. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +136.92% Upside potential.
What Is the CORT Premarket Price?
CORT's last pre-market stock price is 40.99. The pre-market share volume is 500.00, and the stock has decreased by 0.29, or 0.71%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.